Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

63 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Clinical characteristics and outcomes of patients with Hodgkin lymphoma with central nervous system involvement: An international multicenter collaboration.
Cheah CY, Bröckelmann PJ, Chihara D, Moskowitz AJ, Engert A, Jerkeman M, El-Galaly TC, Augustson B, Vose J, Bartlett NL, Villa D, Connors JM, Feldman T, Pinnix CC, Milgrom SA, Dabaja B, Oki Y, Fanale MA. Cheah CY, et al. Among authors: augustson b. Am J Hematol. 2016 Sep;91(9):894-9. doi: 10.1002/ajh.24429. Epub 2016 Jun 20. Am J Hematol. 2016. PMID: 27222367 Free article.
The addition of dexamethasone to bortezomib for patients with relapsed multiple myeloma improves outcome but ongoing maintenance therapy has minimal benefit.
Harrison SJ, Quach H, Link E, Feng H, Dean J, Copeman M, Van De Velde H, Schwarer A, Baker B, Spencer A, Catalano J, Campbell P, Augustson B, Romeril K, Prince HM. Harrison SJ, et al. Among authors: augustson b. Am J Hematol. 2015 May;90(5):E86-91. doi: 10.1002/ajh.23967. Epub 2015 Feb 27. Am J Hematol. 2015. PMID: 25651830 Free article. Clinical Trial.
COO and MYC/BCL2 status do not predict outcome among patients with stage I/II DLBCL: a retrospective multicenter study.
Barraclough A, Alzahrani M, Ettrup MS, Bishton M, van Vliet C, Farinha P, Gould C, Birch S, Sehn LH, Sovani V, Ward MS, Augustson B, Biccler J, Connors JM, Scott DW, Gandhi MK, Savage KJ, El-Galaly T, Villa D, Cheah CY. Barraclough A, et al. Among authors: augustson b. Blood Adv. 2019 Jul 9;3(13):2013-2021. doi: 10.1182/bloodadvances.2019000251. Blood Adv. 2019. PMID: 31285189 Free PMC article.
Renal Impairment at Diagnosis in Myeloma: Patient Characteristics, Treatment, and Impact on Outcomes. Results From the Australia and New Zealand Myeloma and Related Diseases Registry.
Ho PJ, Moore EM, McQuilten ZK, Wellard C, Bergin K, Augustson B, Blacklock H, Harrison SJ, Horvath N, King T, Mollee P, Quach H, Reid C, Rosengarten B, Walker P, Wood EM, Spencer A. Ho PJ, et al. Among authors: augustson b. Clin Lymphoma Myeloma Leuk. 2019 Aug;19(8):e415-e424. doi: 10.1016/j.clml.2019.05.010. Epub 2019 May 16. Clin Lymphoma Myeloma Leuk. 2019. PMID: 31208889
Real-world utilisation of ASCT in multiple myeloma (MM): a report from the Australian and New Zealand myeloma and related diseases registry (MRDR).
Bergin K, Wellard C, Augustson B, Cooke R, Blacklock H, Harrison SJ, Ho J, King T, Quach H, Mollee P, Walker P, Moore E, McQuilten Z, Wood E, Spencer A; Australian and New Zealand Myeloma and Related Diseases Registry. Bergin K, et al. Among authors: augustson b. Bone Marrow Transplant. 2021 Oct;56(10):2533-2543. doi: 10.1038/s41409-021-01308-8. Epub 2021 May 19. Bone Marrow Transplant. 2021. PMID: 34011965
Daratumumab-Based Treatment for Immunoglobulin Light-Chain Amyloidosis.
Kastritis E, Palladini G, Minnema MC, Wechalekar AD, Jaccard A, Lee HC, Sanchorawala V, Gibbs S, Mollee P, Venner CP, Lu J, Schönland S, Gatt ME, Suzuki K, Kim K, Cibeira MT, Beksac M, Libby E, Valent J, Hungria V, Wong SW, Rosenzweig M, Bumma N, Huart A, Dimopoulos MA, Bhutani D, Waxman AJ, Goodman SA, Zonder JA, Lam S, Song K, Hansen T, Manier S, Roeloffzen W, Jamroziak K, Kwok F, Shimazaki C, Kim JS, Crusoe E, Ahmadi T, Tran N, Qin X, Vasey SY, Tromp B, Schecter JM, Weiss BM, Zhuang SH, Vermeulen J, Merlini G, Comenzo RL; ANDROMEDA Trial Investigators. Kastritis E, et al. N Engl J Med. 2021 Jul 1;385(1):46-58. doi: 10.1056/NEJMoa2028631. N Engl J Med. 2021. PMID: 34192431 Clinical Trial.
Isatuximab plus carfilzomib and dexamethasone in patients with relapsed multiple myeloma based on prior lines of treatment and refractory status: IKEMA subgroup analysis.
Dimopoulos MA, Moreau P, Augustson B, Castro N, Pika T, Delimpasi S, De la Rubia J, Maiolino A, Reiman T, Martinez-Lopez J, Martin T, Mikhael J, Yong K, Risse ML, Asset G, Marion S, Hajek R. Dimopoulos MA, et al. Among authors: augustson b. Am J Hematol. 2023 Jan;98(1):E15-E19. doi: 10.1002/ajh.26602. Epub 2022 Jun 4. Am J Hematol. 2023. PMID: 35604280 Free PMC article. No abstract available.
Treatment of patients with multiple myeloma who are eligible for stem cell transplantation: position statement of the Myeloma Foundation of Australia Medical and Scientific Advisory Group.
Quach H, Joshua D, Ho J, Szer J, Spencer A, Harrison SJ, Mollee P, Roberts AW, Horvath N, Talaulikar D, To B, Zannettino A, Brown R, Catley L, Augustson B, Jaksic W, Gibson J, Prince HM. Quach H, et al. Among authors: augustson b. Intern Med J. 2015 Jan;45(1):94-105. doi: 10.1111/imj.12640. Intern Med J. 2015. PMID: 25582938 Review.
Addition of elotuzumab to lenalidomide and dexamethasone for patients with newly diagnosed, transplantation ineligible multiple myeloma (ELOQUENT-1): an open-label, multicentre, randomised, phase 3 trial.
Dimopoulos MA, Richardson PG, Bahlis NJ, Grosicki S, Cavo M, Beksaç M, Legieć W, Liberati AM, Goldschmidt H, Belch A, Magen H, Larocca A, Laubach JP, Petrucci MT, Reece D, White D, Mateos MV, Špička I, Lazaroiu M, Berdeja J, Kaufman JL, Jou YM, Ganetsky A, Popa McKiver M, Lonial S, Weisel K; ELOQUENT-1 investigators. Dimopoulos MA, et al. Lancet Haematol. 2022 Jun;9(6):e403-e414. doi: 10.1016/S2352-3026(22)00103-X. Epub 2022 May 9. Lancet Haematol. 2022. PMID: 35550060 Free article. Clinical Trial.
63 results